See original articles in Unpad: http://journal.fk.unpad.ac.id/index.php/mkb/article/download/1278/pdf
Mesenchymal Stem Cells (MSCs) have immunoregulation and regeneration capabilities through suppression of proinflammatory mediator release and increase of proliferative molecules, particularly the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) TNF-α activated MSC in a certain dose has the ability to increase VEGF and PDGF levels; however, the exact optimum dose of TNF-α to optimize the levels of VEGF and PDGF is unclear.
In this study, TNF-α dose variations were used to determine the optimum, low, and high doses of TNF-α in optimizing VEGF and PDGF expression. This was a post-test only control group study with five study groups consisting of one control (K) and four treatment groups(P). The treatment groups were treated with 5, 10, 40 and 80 ng/mL of TNF-α for 24 hours. PDGF and VEGF levels were measured using ELISA. This study was conducted between September–November 2017 at the Stem Cell and Cancer Research Laboratory (SCCR), Faculty of Medicine, Sultan Agung Islamic University, Semarang.
The results show significant increased in PDGF and VEGF levels (p<0.05) starting from TNF-α 5 ng/mL as the initiation dose to 10 ng/mL as the optimum dose and reduction was seen starting from 40 ng/mL dose. TNF-induced MSCs have the ability to increase the VEGF and PDGF levels with an optimum dose of 10 ng/mL.
Key words: MSC, PDGF, TNF-α, VEGF